Revolution Medicines shared Phase III clinical trial results for a pill called daraxonrasib in patients with previously ...

Revolution Medicines jumps 41% as phase III data show daraxonrasib boosts survival in metastatic PDAC, paving the way for ...

Trial met all primary and key secondary endpoints, including progression-free survival and overall survival -- Company intends to include these data in a future New Drug Application submission to the ...

In a Phase III trial, Revolution Medicines' daraxonrasib almost doubled the survival length of people with advanced ...

By Sriparna Roy April 13 (Reuters) - Revolution Medicines' experimental oral drug helped patients with pancreatic cancer live ...

A new pancreatic cancer drug called daraxonrasib cut the risk of death by 60% in a Phase 3 trial. What it is, how it works, ...

The subject of buyout rumors this year, Revolution posted Phase 3 results one analyst called a “game changer” in a ...

Revolution Medicines (NASDAQ:RVMD) surged 33% on Monday after announcing positive topline findings from its Phase 3 RASolute ...

Revolution Medicines’ pan-RAS inhibitor helped patients with a highly aggressive form of pancreatic cancer live an average of six months longer than chemotherapy, hitting a goal of the phase 3 study.

Former Sen. Ben Sasse is taking Revolution Medicines' daraxonrasib, which has shown promise as a treatment for pancreatic ...

In the intent-to-treat population, the median OS was 13.2 months with daraxonrasib vs 6.7 months for chemotherapy, ...

The RAS family commonly drives the growth and survival of human cancers. Mutations in KRAS, NRAS, and HRAS occur in approximately 20% of all human cancers, including solid tumors, such as pancreatic, ...